- Latest available (Revised)
- Original (As made)
This is the original version (as it was originally made). This item of legislation is currently only available in its original format.
3. In Schedule 3A to the principal Order(1) (substances which may be prescribed, administered or directed for administration by extended formulary nurse prescribers and conditions for such prescription or administration), in the table—
(a)for the entry “Clavulanic acid”, in column 1 add “(as potassium clavulanate)” after “Clavulanic acid”;
(b)for the entry “Hydrocortisone acetate”, in column 2 add “or aural” after “External use”;
(c)for the entry “hyoscine butylbromide”, in column 2 omit “or transdermal” after “Parenteral”; and
(d)in column 1 insert, at the appropriate place in the alphabetical order of the entries as they appear in that column, the entry set out in column 1 below, and in column 2 insert, against that entry, the corresponding entry in column 2 below—
Column 1 | Column 2 |
---|---|
Hyoscine | Transdermal administration in palliative care |
Schedule 3A was inserted by S.I. 2002/549, and amended by S.I. 2003/696, 2003/ 2915 and 2004/2.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: